Avanir Pharma Reports Publication of PRISM Registry Findings

Avanir Pharmaceuticals, Inc.

today announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to further understand prevalence and impact of pseudobulbar affect (PBA) in the United States. A link to the online article can be accessed at http://dx.plos.org/10.1371/journal.pone.0072232. PRISM investigators enrolled 5290 patients with six common neurologic conditions often associated with PBA. More than one third of enrolled patients (n = 1944; 36.7%) had a CNS-LS score ≥13, suggesting PBA symptoms. The impact of the patient's neurological condition on quality of life (QOL) was significantly higher (worse) in these patients (mean score 6.7 vs. 4.7; P<0.0001). In addition, a greater percentage of patients with CNS-LS score ≥13 were being treated with antidepressant/antipsychotic medications (53.0% vs. 35.4%, respectively; P<0.0001).